- Patients with advanced follicular lymphoma (FL) treated with frontline rituximab-based therapy achieved excellent long-term survival with approximately 13 years of follow-up, regardless of the use of intensified or conventional treatment.
Why this matters
- This study has the longest follow-up data reported in this setting.
- Study to investigate the superiority of high-dose chemotherapy+rituximab and autologous hematopoietic stem cell transplantation (R-HDS) vs conventional R-CHOP chemoimmunotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone) as frontline treatment in 136 patients with Ann Arbor stage III/IV FL.
- Funding: Ministero Italiano Università e Ricerca; Banca del Piemonte; Compagnia di San Paolo; Regione Piemonte; Roche.
- 68.5% 13-year estimated OS with R-CHOP vs 64.5% with R-HDS (P=.523).
- 59.1% of patients achieved complete remission (CR) with R-CHOP vs 86.7% with R-HDS.
- In multivariate analysis (without polymerase chain reaction), achievement of CR was the strongest factor for improved survival (HR for CR vs no CR, 3.82; 95% CI, 2.12-6.89; P<.001>
- 26.6% 13-year estimated EFS with R-CHOP vs 48.5% with R-HDS (P=.002).
- 28.8% 13-year estimated PFS with R-CHOP vs 59.1% with R-HDS (P<.001>
- Clinical prognostic scores have since been updated.